Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Edrophonium→

Edrophonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
312-48-1
Molecular formula
C10H16NO+
Molecular weight
166.24 g/mol
Drug class
Short-acting reversible acetylcholinesterase inhibitordiagnostic cholinergic agent
Mechanism of action
Reversibly inhibits acetylcholinesterase, transiently increasing acetylcholine concentration at neuromuscular junctions and enhancing neuromuscular transmission.
Indications / reported uses
  • Historically used as a diagnostic aid in suspected myasthenia gravis (Tensilon test) and for reversal assessment of non-depolarising neuromuscular blockade; availability is limited and diagnostic use has largely been superseded by antibody and electrophysiological testing

Sources: NLM MeSH — Edrophonium · PubMed — Edrophonium test myasthenia gravis · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Edrophonium Environmental Risk Assessment (ERA) (the Edrophonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.